文献速递心脑血管急症消化、代谢与肾脏急症

当代激素避孕与卒中及心肌梗死:全国性真实世界前瞻性队列研究

Stroke and myocardial infarction with contemporary hormonal contraception: real-world, nationwide, prospective cohort study.
PubMed 文献 · BMJ · 2025-02-12
一句话结论丹麦全国队列显示,当代雌激素-孕激素及部分孕激素单药避孕与缺血性卒中及部分心肌梗死风险升高相关,但左炔诺孕酮释放宫内节育器与两者均无关。

该研究基于丹麦国家登记数据,纳入1996至2021年间15-49岁、无动脉或静脉血栓史等排除条件的女性2 025 691例,随访22 209 697人年,首次出院诊断缺血性卒中4730例、心肌梗死2072例。与未使用相比,当前使用复方口服避孕药者缺血性卒中调整率比为2.0(1.9-2.2)、心肌梗死为2.0(1.7-2.2);孕激素单药口服者分别为1.6(1.3-2.0)和1.5(1.1-2.1)。复方阴道环、贴片和孕激素单药皮下埋植也观察到动脉血栓风险升高,而孕激素单药宫内节育器未观察到风险升高(缺血性卒中1.1(1.0-1.3)、心肌梗死1.1(0.9-1.3))。作者认为绝对风险虽低,但临床医生在处方激素避孕方法时应将动脉血栓潜在风险纳入获益-风险评估。

要点

  • 与未使用相比,当前使用复方口服避孕药者缺血性卒中调整率比2.0(1.9-2.2),心肌梗死调整率比2.0(1.7-2.2)。
  • 与未使用相比,当前使用孕激素单药口服者缺血性卒中调整率比1.6(95%CI 1.3-2.0),心肌梗死调整率比1.5(1.1-2.1)。
  • 复方阴道环缺血性卒中调整 incidence rate ratio 2.4(1.5-3.7)、心肌梗死3.8(2.0-7.3);贴片分别为3.4(1.3-9.1)和无心肌梗死;孕激素单药皮下埋植分别为2.1(1.2-3.8)和≤3例心肌梗死。
  • 孕激素单药宫内节育器与缺血性卒中(1.1(1.0-1.3))和心肌梗死(1.1(0.9-1.3))风险升高无关。
  • 作者认为临床医生在处方激素避孕方法时应将动脉血栓潜在风险纳入获益-风险评估。

适用人群与场景

  • 1996至2021年间居住在丹麦的所有15-49岁女性。
  • 排除有动脉或静脉血栓史、使用抗精神病药、癌症、血栓形成倾向、肝脏疾病、肾脏疾病、多囊卵巢综合征、子宫内膜异位症、不孕治疗、激素治疗使用、卵巢切除术和子宫切除术者。

研究设计与关键结果

  • 研究类型:全国性真实世界前瞻性队列研究,基于丹麦国家登记数据;纳入2 025 691名女性,随访22 209 697人年。
  • 主要终点:首次出院诊断缺血性卒中4730例、心肌梗死2072例。
  • 标准化缺血性卒中率每10万人年:未使用18(95%CI 18-19),复方口服避孕药39(36-42),孕激素单药口服33(25-44),宫内节育器23(17-29)。
  • 标准化心肌梗死率每10万人年:未使用8(8-9),复方口服避孕药18(16-20),孕激素单药口服13(8-19),宫内节育器11(7-16)。
  • 与未使用相比,当前使用复方口服避孕药:缺血性卒中调整率比2.0(1.9-2.2),心肌梗死调整率比2.0(1.7-2.2);标准化率差为每10万人年额外21(18-24)例缺血性卒中和10(7-12)例心肌梗死。
  • 与未使用相比,当前使用孕激素单药口服:缺血性卒中调整率比1.6(95%CI 1.3-2.0),心肌梗死调整率比1.5(1.1-2.1);标准化率差为每10万人年额外15(6-24)例缺血性卒中和4(-1-9)例心肌梗死。
  • 复方阴道环:缺血性卒中调整发病率比2.4(1.5-3.7),心肌梗死3.8(2.0-7.3);贴片:缺血性卒中3.4(1.3-9.1),无心肌梗死;孕激素单药皮下埋植:缺血性卒中2.1(1.2-3.8),≤3例心肌梗死。
  • 孕激素单药宫内节育器:缺血性卒中调整发病率比1.1(1.0-1.3),心肌梗死1.1(0.9-1.3),未观察到风险升高。

证据类型、等级与局限

  • 证据类型:全国性真实世界前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,临床医生在处方激素避孕方法时应将动脉血栓潜在风险纳入获益和风险评估。
  • 与未使用相比,复方口服避孕药、孕激素单药口服、复方阴道环、贴片和孕激素单药皮下埋植与缺血性卒中风险升高相关,部分与心肌梗死风险升高相关;孕激素单药宫内节育器与两者均无关。
  • 绝对风险虽低,但原文未给出据此改变具体避孕选择的推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the association between contemporary hormonal contraceptive use and the risk of incident ischaemic stroke and myocardial infarction.

DESIGN: Real-world, nationwide, prospective cohort study.

SETTING: Denmark, by use of national registries.

PARTICIPANTS: All women aged 15-49 years residing in Denmark between 1996 and 2021, with no history of arterial or venous thrombosis, antipsychotics use, cancer, thrombophilia, liver disease, kidney disease, polycystic ovary syndrome, endometriosis, infertility treatment, hormone therapy use, oophorectomy, and hysterectomy.

MAIN OUTCOME MEASURES: First time diagnosis of ischaemic stroke or myocardial infarction at discharge.

RESULTS: Among 2 025 691 women followed up for 22 209 697 person years, 4730 ischaemic strokes and 2072 myocardial infarctions occurred. Standardised ischaemic stroke rate per 100 000 person years were 18 (95% confidence interval 18 to 19) for no use, 39 (36 to 42) for combined oral contraception, 33 (25 to 44) for progestin-only pills, and 23 (17 to 29) for intrauterine device. Standardised myocardial infarction rate per 100 000 person years were 8 (8 to 9) for no use, 18 (16 to 20) for combined oral contraception, 13 (8 to 19) for progestin-only pills, and 11 (7 to 16) for intrauterine device. Compared with no use, current use of combined oral contraception was associated with an adjusted rate ratio of 2.0 (1.9 to 2.2) for ischaemic stroke and 2.0 (1.7 to 2.2) for myocardial infarction. These corresponded to standardised rate differences of 21 (18 to 24) extra ischaemic strokes and 10 (7 to 12) extra myocardial infarctions per 100 000 person years. Compared with no use, current use of progestin-only pills was associated with an adjusted rate ratio of 1.6 (95% CI 1.3 to 2.0) for ischaemic stroke and 1.5 (1.1 to 2.1) for myocardial infarction, equating to 15 (6 to 24) extra ischaemic strokes and four (-1 to 9) extra myocardial infarctions per 100 000 person years. Increased arterial thrombotic risk was also observed with use of the combined vaginal ring (adjusted incidence rate ratio of 2.4 (1.5 to 3.7) for ischaemic stroke and 3.8 (2.0 to 7.3) for myocardial infarction), patch (3.4 (1.3 to 9.1) and no myocardial infarctions), and progestin-only implant (2.1 (1.2 to 3.8) and ≤3 myocardial infarctions), whereas no increased risk was observed with progestin-only intrauterine device (1.1 (1.0 to 1.3) for ischaemic stroke and 1.1 (0.9 to 1.3) for myocardial infarction).

CONCLUSIONS: Use of contemporary oestrogen-progestin and progestin-only contraceptives was associated with an increased risk of ischaemic stroke and, in some cases, myocardial infarction except for the levonorgestrel-releasing intrauterine device, which was not associated with either. Although absolute risks were low, clinicians should include the potential risk of arterial thrombosis in their assessment of the benefits and risks when prescribing a hormonal contraceptive method.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Yonis H, Løkkegaard E, Kragholm K, et al. Stroke and myocardial infarction with contemporary hormonal contraception: real-world, nationwide, prospective cohort study. BMJ. 2025. PMID: 39938934. doi:10.1136/bmj-2024-082801

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。